Srilatha Edupuganti

Emory University — United States

Immunology and Microbiology · Life Sciences

45h-index13.7kcitations160works3.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV Research and Treatment(52), SARS-CoV-2 and COVID-19 Research(40), HIV/AIDS drug development and treatment(32), COVID-19 Clinical Research Studies(27), Influenza Virus Research Studies(20)

Publications154 total

Associations between gender and solicited adverse events after passive infusion of VRC01 or placebo in HVTN 704/HPTN 085
UNC Libraries·2025Open Access
VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials
2025· 1 citedOpen Access
The XBB.1.5 COVID-19 vaccine elicits a durable antibody response to ancestral and XBB.1.5 SARS-CoV-2 spike proteins
Science Translational Medicine·2025· 1 citedOpen Access
Regulation of CD45 isoforms during human effector and memory CD8 T cell differentiation: Implications for T cell nomenclature
Proceedings of the National Academy of Sciences·2025· 2 citedOpen Access
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials
2025· 1 citedOpen Access
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study
EBioMedicine·2025Open Access
Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans
Science·2025· 30 citedOpen Access
Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccines
Frontiers in Immunology·2025· 2 citedOpen Access
Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine
The Journal of Infectious Diseases·2025· 2 cited
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
UNC Libraries·2025Open Access
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
BMC Immunology·2025· 3 citedOpen Access
Rare twin cysteine residues in the HIV-1 envelope variable region 1 link to neutralization escape and breadth development
Cell Host & Microbe·2025· 2 citedOpen Access
Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
UNC Libraries·2025Open Access
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
UNC Libraries·2025Open Access
Oral Preexposure Prophylaxis Uptake and Discontinuation in the HIV Vaccine Trials Network 704/HIV Prevention Trials Network 085 Study: Implications for Biomedical Human Immunodeficiency Virus Prevention Trials
UNC Libraries·2025Open Access
Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women
UNC Libraries·2025Open Access
Fixed Dosing Versus Weight-Based Dosing of HIV-1 Prophylactic Monoclonal Antibodies in Adults: A Pharmacokinetics Modeling Study
SSRN Electronic Journal·2025Open Access
Brief Report: Associations Between Gender and Solicited Adverse Events After Passive Infusion of VRC01 or Placebo in HVTN 704/HPTN 085
JAIDS Journal of Acquired Immune Deficiency Syndromes·2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
The Lancet HIV·2024· 7 citedOpen Access
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
UNC Libraries·2024Open Access
page 1 of 8Next →

Frequent Co-authors

Mark J. Mulligan(27), Nadine Rouphael(25), Rafi Ahmed(15), Mehul S. Suthar(14), Evan J. Anderson(13), Jens Wrammert(13), Lilin Lai(11), Lisa A. Jackson(10), M. Juliana McElrath(10), David S. Stephens(10), David C. Montefiori(8), Grace Mantus(8), Katharine Floyd(7), Lindsay E. Nyhoff(7), Aneesh K. Mehta(6), Robert L. Atmar(6), Hana M. El Sahly(6), Christina A. Rostad(6), Venkata Viswanadh Edara(6), Lawrence Corey(6)